Sanofi Pasteur, the vaccines division of Sanofi, announced that the FDA has approved the supplemental biologics license application for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent vaccine. Fluzone Quadrivalent vaccine is the newest addition to the Fluzone family of influenza vaccines. Like Sanofi Pasteur's Fluzone vaccine, which is administered to more than 50 million people in the U.S. each year, Fluzone Quadrivalent vaccine is licensed for use in children six months of age and older, adolescents, and adults.
- Pharmaceuticals & Drug Trials
- Sanofi Pasteur
- influenza vaccine